INTRODUCTION TO THE AGENUS CLASs ACTION LAWSUIT Contact us today for a free case evaluation in the Agenus class action lawsuit
The Agenus class action lawsuit seeks to represent purchasers or acquirers of Agenus Inc. (NASDAQ: AGEN) publicly traded securities between January 23, 2023, and July 17, 2024, inclusive (the “Class Period”). Captioned Olsen v. Agenus Inc., No. 24-cv-12299 (D. Mass.), the Agenus class action lawsuit charges Agenus and certain of Agenus’ top executives with violations of the Securities Exchange Act of 1934.
If you have suffered losses in Agenus stock and are interested in becoming the lead plaintiff in the Agenus class action lawsuit or have any inquiries regarding your rights as a shareholder, please reach out to Agenus Stock Loss Lawyer Timothy L. Miles at no cost. You can contact him by calling 855/846-6529, sending an e-mail to [email protected], or filling out a contact form below. Lead plaintiff motions for the Agenus class action lawsuit must be filed with the court no later than November 5, 2024. Read on for answers to seven of the most frequently asked questions from investors about the Agenus class action lawsuit. what are the allegations in the Agenus CLASS ACTION lawsuit?
Agenus, a clinical-stage biotechnology company focused on immuno-oncology products, faces serious allegations in the Agenus class action lawsuit. Here are the main points:
• Misleading Statements: Defendants allegedly made false and/or misleading statements throughout the Class Period. • Overstated Efficacy: The lawsuit claims the combination therapy of botensilimab and balstilimab was less effective than investors were led to believe. • Exaggerated Results: Clinical results, regulatory prospects, and commercial potential of botensilimab and balstilimab were allegedly overstated. • FDA Setback: On July 18, 2024, Agenus revealed that the FDA advised against submitting results for Accelerated Approval, citing concerns that "objective response rates may not translate to survival benefit." • Stock Price Plummet: Following the FDA news, Agenus stock price plunged nearly 59%, devastating investors. • Specific Products in Question:
• Investor Deception: Plaintiffs argue that investors were misled about the true potential of Agenus' key product candidates. • Regulatory Hurdles: The FDA's advice against submission for Accelerated Approval raises questions about the company's regulatory strategy. • Financial Impact: The dramatic stock price drop highlights the significant financial consequences of the alleged misrepresentations. when is the THE LEAD PLAINTIFF DEADLINE IN THE CLASS ACTION against Agenus?
Lead plaintiff motions for the Agenus class action lawsuit must be filed with the court no later than November 5, 2024. When a securities class action is filed such as the Agenus class action lawsuit:
what is the THE LEAD PLAINTIFF PROCESS IN THE Agenus class action LAWSUIT?
Under the Private Securities Litigation Reform Act of 1995 (PSLRA):
what are THE BENEFITS OF SERVING AS A LEAD PLAINTIFF IN THE Agenus CLASS ACTION LAWSUIT?
what are THE RESPONSIBILITIES THE LEAD PLAINTIFF WILL HAVE IN THE Agenus CLASS ACTION LAWSUIT?
what are the ELIGIBILITY CRITERIA FOR LEAD PLAINTIFF APPOINTMENT IN THE Agenus CLASS ACTION LAWSUIT?
To be eligible for appointment as the lead plaintiff in the Agenus class action lawsuit, an investor must meet the following criteria:
what are the LEGAL REQUIREMENTS FOR PREVAILING IN THE Agenus CLASS ACTION LAWSUIT?
Resources for Investors in the AGENUS Class Action Lawsuit and OthersCONTACT Agenus STOCK LOSS LAWYER TODAY TIMOTHY L MILES TODAY ABOUT An Agenus CLASS ACTION LAWSUIT
If you suffered losses in Agenus stock, contact Agenus stock loss lawyer Timothy L. Miles today for a free case evaluation about a Agenus class action lawsuit. Call today and see what an Agenus stock loss lawyer could do for you if you suffered losses in Agenus stock. This will most likely be the only call you need to make. (855) 846–6529 or [email protected].
The Law Offices of Timothy L. Miles
Tapestry at Brentwood Town Center 300 Centerview Dr., #247 Brentwood, TN 37027 Phone: (855) 846–6529 Email: [email protected] Agenus stock loss lawyer Timothy L. MilesNashville attorney Timothy L. Miles is a nationally recognized shareholder rights attorney raised in Nashville, Tennessee. Mr. Miles has dedicated his career to representing shareholders, employees, and consumers in complex class-action litigation. Whether serving as lead, co-lead, or liaison counsel, Mr. Miles has helped recover hundreds of millions of dollars for defrauded investors, shaped precedent-setting decisions, and delivered real corporate governance reforms. Judges and peers have repeatedly recognized Mr. Miles’ relentless advocacy for the underdog, as well as his unbendable ethical standards. Mr. Miles was recently selected by Martindale-Hubbell® and ALM as a 2022 Top Ranked Lawyer, 2022 Top Rated Litigator. and a 2022 Elite Lawyer of the South. Mr. Miles also maintains the AV Preeminent Rating by Martindale-Hubbell®, their highest rating for both legal ability and ethics. Mr. Miles is a member of the prestigious Top 100 Civil Plaintiff Trial Lawyers: The National Trial Lawyers Association,Class Action: Class Action: Top National Trial Lawyers, National Trial Lawyers Association (2023), a superb rated attorney by Avvo, a recipient of the Lifetime Achievement Award by Premier Lawyers of America (2019) and recognized as a Distinguished Lawyer, Recognizing Excellence in Securities Law, by Lawyers of Distinction (2019); a Top Rated Litigator by Martindale-Hubbell® and ALM (2019-2022); America’s Most Honored Lawyers 2020 – Top 1% by America’s Most Honored (2020-2022). Mr. Miles has published over sixty articles on various issues of the law, including class actions, whistleblower cases, products liability, civil procedure, derivative actions, corporate takeover litigation, corporate formation, mass torts, dangerous drugs, and more. Please visit our website or call for free anytime. Comments are closed.
|
Hours |
|
